1/31/2024 0 Comments Stem stock price target![]() ![]() The stock was purchased at an average price of $4.82 per share, with a total value of $298,840.00. Buzby purchased 62,000 shares of the company’s stock in a transaction on Friday, September 15th. On average, equities research analysts forecast that Stem will post -1.18 earnings per share for the current year. The business had revenue of $133.74 million during the quarter, compared to analysts’ expectations of $182.46 million. Stem had a negative return on equity of 26.56% and a negative net margin of 30.70%. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. Stem ( NYSE:STEM – Get Free Report) last released its earnings results on Thursday, November 2nd. The company has a current ratio of 1.90, a quick ratio of 1.65 and a debt-to-equity ratio of 1.15. The stock has a market cap of $539.40 million, a price-to-earnings ratio of -2.72 and a beta of 1.91. Stem has a 1-year low of $2.33 and a 1-year high of $11.78. The stock has a 50-day moving average of $3.32 and a 200-day moving average of $4.84. Shares of STEM stock opened at $3.46 on Friday. Based on data from MarketBeat, Stem currently has an average rating of Hold and an average price target of $9.14. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. Finally, Barclays decreased their target price on Stem from $6.00 to $5.00 and set an equal weight rating for the company in a research report on Tuesday, October 24th. Piper Sandler decreased their target price on Stem from $5.00 to $4.00 and set a neutral rating for the company in a research report on Friday, October 6th. Evercore ISI raised their target price on Stem from $11.00 to $17.00 and gave the stock an outperform rating in a research report on Friday, September 8th. Roth Mkm dropped their price target on Stem from $6.00 to $3.70 and set a neutral rating on the stock in a report on Wednesday, November 1st. They set a neutral rating and a $5.00 target price for the company. BNP Paribas started coverage on Stem in a research note on Friday, October 20th. Several other equities research analysts have also recently commented on the company. The brokerage currently has an equal weight rating on the stock. He expects those numbers will improve to EBITDA of positive $5.4-million on a topline of $766.5-million the following year.Stem ( NYSE:STEM – Free Report) had its price target lowered by Morgan Stanley from $7.00 to $4.00 in a report issued on Friday morning, Benzinga reports. ![]() The analyst thinks STEM will EBITDA of negative $23.8-million on revenue of $550.6-million in fiscal 2023. In a research update to clients November 6, Clare maintained his “Neutral” rating and twelve-month target price of $3.70 on STEM. Despite the strength in orders, we are incrementally less positive on the outlook for hardware margins given the downward revision to prior hardware revenue and the margin implications.Īdditionally, we continue to look for acceleration in battery software revenue, which declined 29% QoQ. Demand appears strong as STEM’s bookings of $676mn were well above guidance and CARR increased 17% QoQ. “STEM delivered a Q3 miss and narrowed the 2023 EBITDA guidance range,” he said. We are raising our CARR guidance based on our strong bookings, which we believe positions us well to grow our high-margin software and services revenue in 2024 and beyond. “Our bookings grew more than 3x versus the same quarter last year, which led to a 17% sequential increase in CARR. “We generated strong results in the third quarter, highlighted by record bookings, AUM, CARR, and contracted backlog,” CEO John Carrington said. The company posted Adjusted EBITDA of negative $900,000 on revenue of $133.7-million, a topline that was up 34 per cent over the same period last year. ![]() On November 2, STEM reported its Q3, 2023 results. ![]() (Stem Stock Quote, Chart, News, Analysts, Financials NYSE:STEM) is not a stock you should be buying right now. Following third quarter results that came in below expectations, Roth MKM analyst Justin Clare says Stem Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |